SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Residential Real Estate Crash Index -- Ignore unavailable to you. Want to Upgrade?


To: MulhollandDrive who wrote (181236)2/2/2009 4:40:48 PM
From: Lizzie TudorRead Replies (2) | Respond to of 306849
 
nothing I just think it is wierd that this octomom (LOL- your word, good one) is such a drag on the medical system, primarily from a costs standpoint when common sense dictates her case is somewhere way down there in terms of costs incurred by the system.

The woman is a whack obviously and needs medical care for mental illness it sounds like to me but why the outrage about medical costs?

If I were going to target medical costs I'd start with the drug companies/lobbies, producing wonderful products like this listed below at over $22K per dose, next the medical device makers like hansen medical who produce ONE boutique medical device to sell to hospitals and wind up with a billion dollar market cap because of the gross profitabilty (there are hundreds of companies like this), and finally somewhere down near the bottom of waste is this one stupid woman.

Bexxar from GlaxoSmithKline and Zevalin from Biogen Idec. The drugs are approved as a third-line treatment for non-Hodgkin's lymphoma, a form of cancer that begins in the lymph system, after other treatments have failed. But they are sometimes administered as a first line of attack, a use that is not approved. The medications cost $22,210 for a single dose, which constitutes a full course of treatment, according to spokeswomen for both companies. …
lymphomation.org